Google
CTOR — CITIUS ONCOLOGY, INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
CTOR FAQ
What is CTOR's ROE?
CITIUS ONCOLOGY, INC. reports a Return on Equity (ROE) of -120.53%.
What is CTOR's dividend yield?
CITIUS ONCOLOGY, INC. offers a dividend yield of 0.00%.
What is CTOR's Deepscope Quality Score?
Deepscope rates CTOR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CTOR?
Deepscope's AI Timing Score for CTOR is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CTOR belong to?
CITIUS ONCOLOGY, INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 0.72
Price
-0.03
(-4.58%)
Day Change
|
|
|---|
CTOR, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.72 |
| PBV / Sector |
2.06 / 2.60
|
| Earning Per Share | -0.42 |
| PE / Sector |
N/A / 23.51
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:15 |
| Symbol | CTOR |
| Name | CITIUS ONCOLOGY, INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 92.98 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 72.53 / 9,783.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11 Commerce Drive, Cranford, NJ, United States, 07016
Phone: 908 967 6677
Website: -
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
